Artiva Biotherapeutics, Inc. (ARTV)
NASDAQ: ARTV · Real-Time Price · USD
4.680
+0.150 (3.31%)
At close: Feb 20, 2026, 4:00 PM EST
4.590
-0.090 (-1.92%)
After-hours: Feb 20, 2026, 5:13 PM EST
Artiva Biotherapeutics Revenue
In the year 2024, Artiva Biotherapeutics had annual revenue of $251.00K, down -99.25%.
Revenue (ttm)
$251.00K
Revenue Growth
-99.25%
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
106
Market Cap
114.87M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 251.00K | -33.24M | -99.25% |
| Dec 31, 2023 | 33.49M | 28.56M | 579.21% |
| Dec 31, 2022 | 4.93M | 2.93M | 146.30% |
| Dec 31, 2021 | 2.00M | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| MacroGenics | 127.63M |
| Agenus | 106.83M |
| Fortress Biotech | 62.30M |
| Codexis | 52.93M |
| Seer, Inc. | 16.38M |
| Korro Bio | 7.37M |
| Equillium | 4.39M |
| Coya Therapeutics | 3.99M |
ARTV News
- 1 day ago - Artiva Biotherapeutics Announces Appointment of Elaine Sorg to Board of Directors - GlobeNewsWire
- 4 weeks ago - Artiva Biotherapeutics Announces Upcoming Presentations at the 2026 Transplantation & Cellular Therapy Meetings of ASTCT® and CIBMTR® (Tandem Meetings) Highlighting Cost-Effectiveness of AlloNK in a Community Rheumatology Practice and Continued Durability of AlloNK in NHL - GlobeNewsWire
- 5 weeks ago - Artiva Biotherapeutics: Upcoming Data Presentations May Bring Them Out Of Being Ignored - Seeking Alpha
- 3 months ago - Artiva Biotherapeutics Announces Positive Initial Safety and Translational Data Supporting Deep B-Cell Depletion with AlloNK® in Autoimmune Disease - GlobeNewsWire
- 3 months ago - Artiva Biotherapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights - GlobeNewsWire
- 3 months ago - Artiva Biotherapeutics to Host Virtual Event Discussing Initial Safety and Translational Data in up to 32 Patients with Autoimmune Disease Treated with AlloNK® - GlobeNewsWire
- 4 months ago - Artiva Biotherapeutics to Participate in Upcoming Investor Conferences in November - GlobeNewsWire
- 4 months ago - Artiva Biotherapeutics Announces Refractory Rheumatoid Arthritis as Lead Indication, Upcoming Data Releases, and Corporate Update - GlobeNewsWire